198 related articles for article (PubMed ID: 29047144)
1. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients.
Trifa AP; Bănescu C; Bojan AS; Voina CM; Popa Ș; Vișan S; Ciubean AD; Tripon F; Dima D; Popov VM; Vesa ȘC; Andreescu M; Török-Vistai T; Mihăilă RG; Berbec N; Macarie I; Coliţă A; Iordache M; Cătană AC; Farcaș MF; Tomuleasa C; Vasile K; Truică C; Todincă A; Pop-Muntean L; Manolache R; Bumbea H; Vlădăreanu AM; Gaman M; Ciufu CM; Popp RA
Am J Hematol; 2018 Jan; 93(1):100-106. PubMed ID: 29047144
[TBL] [Abstract][Full Text] [Related]
2. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
3. Germline variations at
Chiang YH; Chang YC; Lin HC; Huang L; Cheng CC; Wang WT; Cheng HI; Su NW; Chen CG; Lin J; Chang YF; Chang MC; Hsieh RK; Chou WC; Lim KH; Kuo YY
Oncotarget; 2017 Sep; 8(44):76204-76213. PubMed ID: 29100304
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W; Jones AV; Kralovics R; Harutyunyan AS; Zoi K; Leung W; Godfrey AL; Guglielmelli P; Callaway A; Ward D; Aranaz P; White HE; Waghorn K; Lin F; Chase A; Baxter EJ; Maclean C; Nangalia J; Chen E; Evans P; Short M; Jack A; Wallis L; Oscier D; Duncombe AS; Schuh A; Mead AJ; Griffiths M; Ewing J; Gale RE; Schnittger S; Haferlach T; Stegelmann F; Döhner K; Grallert H; Strauch K; Tanaka T; Bandinelli S; Giannopoulos A; Pieri L; Mannarelli C; Gisslinger H; Barosi G; Cazzola M; Reiter A; Harrison C; Campbell P; Green AR; Vannucchi A; Cross NC
Nat Commun; 2015 Apr; 6():6691. PubMed ID: 25849990
[TBL] [Abstract][Full Text] [Related]
5. TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
Matsuguma M; Yujiri T; Yamamoto K; Kajimura Y; Tokunaga Y; Tanaka M; Tanaka Y; Nakamura Y; Tanizawa Y
Int J Hematol; 2019 Dec; 110(6):690-698. PubMed ID: 31571131
[TBL] [Abstract][Full Text] [Related]
6. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
7. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
[TBL] [Abstract][Full Text] [Related]
8. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
9. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Ferreira Cristina S; Polo B; Lacerda JF
Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
He ZP; Tian HY; Tan M; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
[TBL] [Abstract][Full Text] [Related]
11. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.
Zhang X; Hu T; Wu Z; Kang Z; Liu W; Guan M
Int J Hematol; 2012 Nov; 96(5):611-6. PubMed ID: 23054641
[TBL] [Abstract][Full Text] [Related]
12. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
13. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
[TBL] [Abstract][Full Text] [Related]
14. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
15. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
[TBL] [Abstract][Full Text] [Related]
16. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J
Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426
[TBL] [Abstract][Full Text] [Related]
17. JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
Tanaka M; Yujiri T; Ito S; Okayama N; Takahashi T; Shinohara K; Azuno Y; Nawata R; Hinoda Y; Tanizawa Y
Int J Hematol; 2013 Mar; 97(3):409-13. PubMed ID: 23430670
[TBL] [Abstract][Full Text] [Related]
18. Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
Cavalloni C; Rumi E; Ferretti VV; Pietra D; Roncoroni E; Bellini M; Ciboddo M; Casetti IC; Landini B; Fugazza E; Troletti D; Astori C; Cazzola M
Oncotarget; 2017 May; 8(20):33416-33421. PubMed ID: 28422716
[TBL] [Abstract][Full Text] [Related]
19. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
20. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
